NewAmsterdam Pharma’s

Financial Adviser

Financial Adviser in NewAmsterdam Pharma’s USD 479 million Public Offering

Transaction highlights

Van Lanschot Kempen acted as Financial Adviser in connection to NewAmsterdam Pharma's USD 479 million US public offering of ordinary shares and pre-funded warrants priced on 11 December 2024
The transaction was launched on the back of positive topline data from the Company’s pivotal phase 3 BROADWAY clinical trial and a share price jump of 48% on the day of the data release
The deal size was upsized from USD 300 million at launch to USD 416.5 million at pricing. Following the exercise of the over-allotment option, the Company raised gross proceeds of USD 479 million
Following a bookbuild period of >24 hours, the transaction priced at $24.50 per share (and $24.4999 per pre-funded warrant), representing a discount of 4.2% to the closing price on 11 December and a premium of 32.3% to the pre-data closing price on 9 December
This transaction marks Van Lanschot Kempen’s second involvement in connection with an equity capital markets transaction in NewAmsterdam Pharma stock, underpinning the capability of Van Lanschot Kempen to add value for recurring US Nasdaq listed clients

Company description

NewAmsterdam Pharma (Nasdaq: NAMS) is a clinical-stage biotechnology company focused on improving patient care in populations with metabolic diseases where currently approved therapies have not been sufficiently successful or tolerated. Its lead candidate, obicetrapib, is an oral, low-dose and once-daily CETP inhibitor, as the currently preferred LDL-C lowering therapy to be used as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease patients. NewAmsterdam Pharma is based in the Netherlands.

Background Van Lanschot Kempen Life Sciences & Healthcare

In the last twelve months, Van Lanschot Kempen has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

Sole Financial Adviser to SNIPR Biome in securing a €20 million venture debt facility from the European Investment Bank
Lead Manager in the USD 1.0 billion Capital Increase by Zealand Pharma
Lead Manager in the USD 460 million Capital Increase by Merus
Sole Financial Adviser to Pharming Group in the refinancing of its convertible bonds
Financial Adviser in the SEK 107 million Rights Issue by Alligator Bioscience
Co-Manager in the USD 350 million Capital Increase by Autolus Therapeutics
Financial Adviser to Galapagos in the €170 million sale of its Jyseleca business to Alfasigma
Sole Financial Adviser to Zealand Pharma in securing a €90 million venture debt facility from the European Investment Bank

Contact

Jan De Kerpel

Mail Jan De Kerpel

Robin van Wijk

Mail Robin van Wijk